KR101756570B1 - 옥사졸리돈계 화합물 및 이의 제조방법과 용도 - Google Patents

옥사졸리돈계 화합물 및 이의 제조방법과 용도 Download PDF

Info

Publication number
KR101756570B1
KR101756570B1 KR1020157021881A KR20157021881A KR101756570B1 KR 101756570 B1 KR101756570 B1 KR 101756570B1 KR 1020157021881 A KR1020157021881 A KR 1020157021881A KR 20157021881 A KR20157021881 A KR 20157021881A KR 101756570 B1 KR101756570 B1 KR 101756570B1
Authority
KR
South Korea
Prior art keywords
compound
group
membered
substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157021881A
Other languages
English (en)
Korean (ko)
Other versions
KR20150105466A (ko
Inventor
유쉐 양
타오 쉐
시 딩
빈 구오
Original Assignee
상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈
저장 주타이 파마스티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈, 저장 주타이 파마스티컬 컴퍼니 리미티드 filed Critical 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈
Publication of KR20150105466A publication Critical patent/KR20150105466A/ko
Application granted granted Critical
Publication of KR101756570B1 publication Critical patent/KR101756570B1/ko
Assigned to 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 reassignment 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 권리지분의 전부이전등록 Assignors: 저장 주타이 파마스티컬 컴퍼니 리미티드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020157021881A 2013-01-18 2013-12-30 옥사졸리돈계 화합물 및 이의 제조방법과 용도 Expired - Fee Related KR101756570B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310020040.8A CN103936763B (zh) 2013-01-18 2013-01-18 噁唑烷酮类化合物及其制备方法和用途
CN201310020040.8 2013-01-18
PCT/CN2013/090833 WO2014110971A1 (zh) 2013-01-18 2013-12-30 噁唑烷酮类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
KR20150105466A KR20150105466A (ko) 2015-09-16
KR101756570B1 true KR101756570B1 (ko) 2017-07-10

Family

ID=51184670

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157021881A Expired - Fee Related KR101756570B1 (ko) 2013-01-18 2013-12-30 옥사졸리돈계 화합물 및 이의 제조방법과 용도

Country Status (8)

Country Link
US (1) US9382265B2 (https=)
EP (1) EP2947085B1 (https=)
JP (1) JP6242915B2 (https=)
KR (1) KR101756570B1 (https=)
CN (1) CN103936763B (https=)
AU (1) AU2013373885B2 (https=)
CA (1) CA2898550C (https=)
WO (1) WO2014110971A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105593232B (zh) * 2013-09-29 2018-06-26 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
WO2015110024A1 (en) * 2014-01-24 2015-07-30 Sunshine Lake Pharma Co., Ltd. Oxazolidinone compounds and their uses in pharmaceuticals
WO2015176677A1 (en) * 2014-05-22 2015-11-26 Sunshine Lake Pharma Co., Ltd. Crystalline forms and amorphism of oxazolidinone compound
CN105693746B (zh) * 2014-06-14 2018-09-14 广东东阳光药业有限公司 噁唑烷酮类化合物的制备方法及其中间体
CN105503903B (zh) * 2014-09-26 2019-04-26 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物的制备方法及其中间体和晶型
CN104672236B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN104610260B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104610258B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN106478658A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型d及其制备方法
CN106478661A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法
CN105348275A (zh) * 2015-12-10 2016-02-24 中国药科大学 噁唑烷酮类化合物及其合成方法与医药应用
CN108069983A (zh) * 2016-11-10 2018-05-25 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型及其制备方法和应用
CN108395442A (zh) * 2017-02-07 2018-08-14 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型vii及其制备方法和应用
CN108727406B (zh) 2017-03-28 2021-12-07 北京协和制药二厂 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
CN108912142B (zh) * 2018-08-08 2021-06-18 延边大学 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途
CN114685529A (zh) * 2020-12-29 2022-07-01 中国科学院上海药物研究所 噁唑烷酮类化合物的无定形物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260277A (zh) * 2010-05-24 2011-11-30 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19805117A1 (de) * 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JPWO2010071164A1 (ja) * 2008-12-19 2012-05-31 第一三共株式会社 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260277A (zh) * 2010-05-24 2011-11-30 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途

Also Published As

Publication number Publication date
CN103936763B (zh) 2017-10-31
JP6242915B2 (ja) 2017-12-06
WO2014110971A1 (zh) 2014-07-24
EP2947085A1 (en) 2015-11-25
AU2013373885B2 (en) 2016-07-14
CA2898550C (en) 2016-08-02
US20150361091A1 (en) 2015-12-17
JP2016513076A (ja) 2016-05-12
CN103936763A (zh) 2014-07-23
EP2947085B1 (en) 2017-09-13
EP2947085A4 (en) 2016-06-22
US9382265B2 (en) 2016-07-05
KR20150105466A (ko) 2015-09-16
AU2013373885A1 (en) 2015-08-27
CA2898550A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
KR101756570B1 (ko) 옥사졸리돈계 화합물 및 이의 제조방법과 용도
US12084452B2 (en) Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
TWI586651B (zh) 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
JP6479763B2 (ja) 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
JP2023501799A (ja) Ｒｏｃｋ阻害剤及びその製造方法と用途
KR102494647B1 (ko) 비시클릭 헤테로아릴 치환된 화합물
CA3128062A1 (en) Benzopyridone heterocyclic compound and use thereof
TW201938561A (zh) 化學化合物
US20150119390A1 (en) Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
CN114591212B (zh) 人类血浆激肽释放酶抑制剂
PL200413B1 (pl) Podstawione oksazolidynony, sposób ich wytwarzania, środki lecznicze je zawierające oraz ich zastosowanie do wytwarzania środków leczniczych i do zapobiegania krzepnięciu krwi ex vivo
KR102492715B1 (ko) 모노시클릭 헤테로아릴 치환된 화합물
CN105026392B (zh) 4,5‑二氢‑吡唑并[3,4‑c]吡啶‑2‑酮衍生物、其制备方法以及应用
CN101151263A (zh) 作为肾素抑制剂的取代的哌啶
CN105218564A (zh) 三环噁唑烷酮类化合物及其制备方法和用途
CN105324382B (zh) 4,5‑二氢吡唑并[3,4‑c]吡啶‑2‑酮的螺环衍生物、其制备方法以及应用
CN104395312B (zh) 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用
CN111303146A (zh) 3-氰基吡啶类化合物、包含其的药物组合物及其制备方法和用途
CN102796092B (zh) 噁唑烷酮衍生物及其制备方法和应用
CN110759901A (zh) 四氢异喹啉类衍生物及其制备方法和用途
CN116829547A (zh) 因子XIIa抑制剂
WO2013151719A2 (en) Fluorinated oxazolidinone derivatives

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240705

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240705